Journal: Metabolites

Article Title: Galectin-1 in Obesity and Type 2 Diabetes

doi: 10.3390/metabo12100930

Figure Lengend Snippet: Original papers on galectin-1 in association with obesity, insulin resistance and type 2 diabetes identified through a structured search in PubMed in August 2022 using the following terms: galectin-1 and obesity, galectin-1 and insulin resistance, galectin-1 and type 2 diabetes, totalling 23 publications.

Article Snippet: Mukherjee R et al. 2016 [ ] , 3T3-L1 and HIB1B cells; NC and HFD Sprague Dawley rats.; inhibition of galectin-1 by lactulose treatment. , 3T3-L1 cells and HIB1B preadipocytes, respectively were cultured and differentiated in the presence of LT; NC, HFD-fed HC, HFD-fed rats treated with LT by oral administration (LT-OR), and HFD-fed rats treated with LT by i.p injection (LT-IP). , LT treatment reduced adipogenesis and fat accumulation in vitro by down-regulation of adipogenic transcription factors such as C/EBPα and PPARγ. In vivo treatment of LT blocked HFD-induced body weight gain and food efficiency and improved metabolic variables in the plasma. Reduced adipogenic (C/EBPα and PPARγ) and increased energy expenditure and lipolysis marker proteins (ATP5B, COXIV, HSL, and CPT1) in adipose tissue..

Techniques: In Vitro, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Expressing, Control, Knock-Out, Isolation, Cell Culture, Injection, Inhibition, In Vivo, Marker, Migration, Genome Wide, Phospho-proteomics, Activity Assay, Blocking Assay, Immunohistochemistry, Binding Assay, Recombinant, Gene Expression